Corrigendum to “78P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC)”
Titel:
Corrigendum to “78P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC)”
Auteur:
Oh, D. He, A.R. Qin, S. Chen, L. Okusaka, T. Vogel, A. Kim, J.W. Suksombooncharoen, T. Lee, M.A. Kitano, M. Burris, H.A. Bouattour, M. Tanasa, S. Zaucha, R.E. Avallone, A. Cundom, J.E. Rokutanda, N. Żotkiewicz, M. Cohen, G. Valle, J.W.